Febrile Neutropenia, Oncopediatrics
Conditions
Brief summary
The goal of this clinical trial is to evaluate the feasibility of the study, measured by the acceptability rate of patients to be recruited in a study proposing temperature monitoring at home, by a remote monitoring device or by the visit of an IDE at home (in association with the usual educational sessions), to children at risk of febrile neutropenia, from families with psycho-social vulnerabilities. The main questions it aims to answer are: * Will participants adhere to the telemonitoring system? * Is the intervention feasible, in terms of the device's failure to record temperature data? * Will parents behave appropriately when using the device? * How satisfied will parents and caregivers be? * What will be the physical tolerance of the device? * On an exploratory basis, will the remote monitoring system be effective for months? Researchers will compare : * patients using the telemonitoring device for continuous temperature monitoring at home, in combination with education sessions on temperature monitoring and the device * with patient with temperature monitoring at home by a nurse, 2 times a day, in combination with education sessions on temperature monitoring (without the telemonitoring device at home)
Interventions
DEVICERemote temperature monitoring device
* Use of the Tucky® remote monitoring device for continuous temperature monitoring at home, * In combination with education sessions on temperature monitoring and the device.
DIAGNOSTIC_TESTHome temperature monitoring by a nurse
* Home temperature monitoring by a nyrse, twice a day, * In association with education sessions on temperature monitoring.
Sponsors
Centre Hospitalier Universitaire de la Réunion
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
0 Years to 17 Years
Healthy volunteers
No
Inclusion criteria
patient * Aged 0 to 17 inclusive * Followed in the Pediatric Onco-Hematology Department * Primo-diagnosed with solid or hematological cancer (incident case) * Having received a first cycle of chemotherapy * Whose family has psycho-social vulnerabilities assessed by the Froger et al. tool, indicating a need for an IDE to support the family in monitoring the patient.
Exclusion criteria
Patient: * with a dermatosis contraindicating the use of the device * Refusing to participate in the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| study acceptability rate | 24 months | number of patients included/number of eligible patients offered the study. |
Contacts
CONTACTVéronique ARMAND
Outcome results
None listed